Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and…
| Price | $10.89 |
|---|---|
| Market cap | $19.38M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 5.61-31 |
| Beta | -0.07 |
Explore PTN's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.